Elicio Therapeutics, which is developing the Irvine Lab’s lymph node targeting vaccine technology, has dosed its first patient of a Phase 1/2 clinical trial of a treatment of KRAS/NRAS mutated solid tumors in pancreatic and colorectal cancer patients.